EMG Differentiation Between COVID-19 Neurological Damage and ALS

Key Distinguishing Features on EMG

Mixed axonal neuropathy and primary myopathy are the predominant neuromuscular findings in COVID-19 patients, particularly those with severe disease requiring ICU care, according to the World of Neurosurgery 1, 2
Critical illness-associated neuromuscular disorders show evidence suggesting direct viral injury of motor units, but these are fundamentally different from motor neuron disease, as reported in the World of Neurosurgery 1
Skeletal muscle injury occurs in 10.7% of COVID-19 cases, presenting with myopathic changes on EMG rather than denervation patterns typical of ALS, as found in studies published in the World of Neurosurgery 3, 4
Upper and lower motor neuron involvement with specific electrodiagnostic criteria that evolve predictably over time, as described in the World of Neurosurgery 3

The presence of fasciculations can be seen in both COVID-19 and ALS, but the distribution and associated findings differ, according to the World of Neurosurgery 3
Nerve conduction studies help identify axonal neuropathy patterns common in COVID-19 versus normal or mildly affected nerves in ALS, as reported in the World of Neurosurgery 3

CNS involvement occurs in 36.4% of COVID-19 cases, presenting with confusion, corticospinal tract signs, and dysexecutive syndrome, which are not typical of pure ALS, as found in studies published in the World of Neurosurgery 3, 5
Encephalopathy, delirium, and altered mental status are prominent COVID-19 features that should prompt consideration of alternative diagnoses, according to the World of Neurosurgery 3, 5

It is difficult to differentiate symptoms due to primary viral injury from those resulting from secondary systemic involvement, particularly in ICU settings, as reported in the World of Neurosurgery 3, 5
Monitor for evolving patterns—COVID-19 neurological manifestations should plateau or improve, while ALS shows inexorable progression, as described in the World of Neurosurgery 3

The available evidence demonstrates neuroinflammation, neuronal injury, and various neurodegenerative processes following COVID-19, but does not support COVID-19 as a trigger for true ALS, according to the American Academy of Neurology 6, 7

COVID-19 causes extensive neurological damage through multiple mechanisms, including neuroinflammation and neuronal injury, with studies showing widespread microglial reactivity, neuronal apoptosis, and brain microhemorrhages even in mild cases, as reported by the National Institute of Neurological Disorders and Stroke 6, 7
Central nervous system involvement occurs in 36.4% of COVID-19 cases overall and 45.5% in severe disease, presenting with dizziness, headache, ataxia, and other neurological symptoms, according to the World Health Organization 7

Cognitive impairment and brain fog persist in 26% of patients at 12 months, representing the most common long-term neurological sequelae, as found by the National Institutes of Health 6
Neuromuscular symptoms, including muscle weakness and fatigue, affect many Long COVID patients, but these stem from microvascular disease, ongoing inflammation, and deconditioning rather than motor neuron degeneration, according to the European Respiratory Society 8, 9
Respiratory muscle weakness is well-documented in post-COVID patients and can be improved with respiratory muscle training, indicating a functional rather than degenerative process, as reported by the American Thoracic Society 9, 10

Consider alternative diagnoses, such as post-viral fatigue, critical illness myopathy/neuropathy, deconditioning, respiratory muscle weakness, and Long COVID neuromuscular manifestations, which are far more likely than new-onset ALS, according to the American Academy of Physical Medicine and Rehabilitation 8, 9, 10